Under construction – not a live service
Sign in
Not yet taking people in FrancePhase 2

Imaging Hand Joint Disease in Osteoarthritis and Rheumatoid Arthritis Using a Radioactive Tracer

Tests a radioactive imaging tracer to find diseased hand joints in adults with arthritis.

Key facts

Who runs it
Centre Jean Perrin
Where
Clermont-Ferrand, FranceSee the 2 sites
Trial code
Registry title
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine
Status
Not yet recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
1 Oct 2026
Expected to end
1 Jul 2028
Type of study
Interventional, 2 groups
Treatments tested
  • 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a recent diagnosis of painful hand osteoarthritis or rheumatoid arthritis. It tests an imaging agent, 99mTc-NTP 15-5, to find affected hand joints.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Rheumatoid arthritis group: certain diagnosis made less than 5 years ago, finger pain above 4 out of 10, and active joint inflammation seen on exam and ultrasound. Hand osteoarthritis group: certain diagnosis of painful hand osteoarthritis made less than 5 years ago, finger pain above 4 out of 10.
Earlier treatment
Hand osteoarthritis group: must stop NSAIDs (anti-inflammatory painkillers) at least 8 days before the injection. Rheumatoid arthritis group: no biologic drugs (anti-TNF alpha, rituximab, abatacept, anti-IL6, anti-JAK) as background treatment. No hand joint steroid injection in the last month.
Biomarker or test result
Women who can have children need a negative blood pregnancy test within 7 days before the injection. Karnofsky index above 70%.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Currently taking NSAIDs
  • Past surgery on the bones or joints of the hand, or hand soft tissue surgery in the last 6 months
  • BMI above 30
  • Known allergy to an ingredient of the 99mTc-NTP 15-5 solution

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Karnofsky index > 70%
  • Obtaining written, signed and dated informed consent
  • Affiliation to a health insurance plan
  • For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period
  • Ability and willingness to respect study visits, exams as well as protocol; RA Group:
  • certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria,
  • symptomatic (finger pain > 4 /10 on a numerical scale),
  • active synovitis (clinical and ultrasound),; Group DOA:
  • certain diagnosis of symptomatic DOA less than 5 years old (finger pain > 4 /10 on a numerical scale),
  • stopping NSAIDs for at least 8 days before the injection,

Who cannot take part

  • Ongoing use of non-steroidal anti-inflammatory drugs,
  • History of osteoarticular hand surgery
  • History of hand soft tissue surgery in the past 6 months
  • History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,
  • Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study; RA Group:
  • Patients with a history of hand DOA
  • Patients or patients 18 years old,
  • Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,
  • Pregnant or breastfeeding patient,
  • IMC>30,
  • Persons deprived of their liberty, under guardianship/curatorship, or safeguarding of justice,
  • Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment

Where in France

  • Centre Jean PerrinClermont-Ferrand, FranceContact: MARION CHANCHOU, MDNo longer taking part
  • CHU Clermont-FerrandClermont-Ferrand, FranceContact: SYLVAIN MATHIEUNo longer taking part

About the trial

What the trial wants to find out

This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis

The 2 groups in the trial

  • Rheumatoid arthritisTreatment being tested

    99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg

    Treatment: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg

  • digital osteoarthritisTreatment being tested

    99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg

    Treatment: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study
Plain-language title
Imaging Hand Joint Disease in Osteoarthritis and Rheumatoid Arthritis Using a Radioactive TracerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
20 October 2026